LinkedIn Profile

Access Enanta Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:enta 40481 Apr 14th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 13th, 2024 10:59PM Apr 14th, 2024 10:57AM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 13th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 12th, 2024 10:50PM Apr 13th, 2024 11:25AM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 12th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 11th, 2024 10:54PM Apr 12th, 2024 08:20AM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 11th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 10th, 2024 11:27PM Apr 11th, 2024 11:04AM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 10th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 9th, 2024 10:57PM Apr 10th, 2024 05:12PM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 9th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 8th, 2024 11:08PM Apr 9th, 2024 09:54AM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 8th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 7th, 2024 11:34PM Apr 8th, 2024 06:52PM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 7th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 6th, 2024 11:04PM Apr 6th, 2024 11:04PM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 6th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 164.00 Open Apr 5th, 2024 11:05PM Apr 5th, 2024 11:05PM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:enta 40481 Apr 5th, 2024 12:00AM Enanta Pharmaceuticals 9.3K 163.00 Open Apr 4th, 2024 11:32PM Apr 4th, 2024 11:32PM Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Open Virology and Immunology Open 500 Arsenal Street Watertown MA US 02472 Enanta Pharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.